Abstract
Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Liver international : official journal of the International Association for the Study of the Liver
Paper Title
Journal
Date
